Shots:

• King’s and Wellcome to receive $340M as development and commercial milestone and royalties on sales. MSD to get a license for conducting lead optimization- preclinical & clinical research
• The focus of an agreement is to develop therapies for chronic pain and to meet unmet medical needs of patients
• Professor McNaughton at King’s identifies target protein- HCN2 which is used by MSD to develop therapies that relieve pain without side effects by blocking HCN2 protein

Ref: King’s College London| Image: MSD